Active site modulation in the N-acetylneuraminate lyase sub-family as revealed by the structure of the inhibitor-complexed Haemophilus influenzae enzyme.
The N-acetylneuraminate lyase (NAL) sub-family of (beta/alpha)(8) enzymes share a common catalytic step but catalyse reactions in different biological pathways. Known examples include NAL, dihydrodipicolinate synthetase (DHDPS), d-5-keto-4-deoxyglucarate dehydratase, 2-keto-3-deoxygluconate aldolase, trans-o-hydroxybenzylidenepyruvate hydrolase-aldolase and trans-2'-carboxybenzalpyruvate hydratase-aldolase. Little is known about the way in which the three-dimensional structure of the respective active sites are modulated across the sub-family to achieve cognate substrate recognition. We present here the structure of Haemophilus influenzae NAL determined by X-ray crystallography to a maximum resolution of 1.60 A, in native form and in complex with three substrate analogues (sialic acid alditol, 4-deoxy-sialic acid and 4-oxo-sialic acid). These structures reveal for the first time the mode of binding of the complete substrate in the NAL active site. On the basis of the above structures, that of substrate-complexed DHDPS and sequence comparison across the sub-family we are able to propose a unified model for active site modulation. The model is one of economy, allowing wherever appropriate the retention or relocation of residues associated with binding common substrate substituent groups. Our structures also suggest a role for the strictly conserved tyrosine residue found in all active sites of the sub-family, namely that it mediates proton abstraction by the alpha-keto acid carboxylate in a substrate-assisted catalytic reaction pathway.
Barbosa
J A
JA
Biomolecular Research Institute, 343 Royal Parade, Parkville, Victoria, Australia.
Smith
B J
BJ
DeGori
R
R
Ooi
H C
HC
Marcuccio
S M
SM
Campi
E M
EM
Jackson
W R
WR
Brossmer
R
R
Sommer
M
M
Lawrence
M C
MC
D000595:Amino Acid Sequence; D001665:Binding Sites; D002384:Catalysis / Q000187:drug effects; D017124:Conserved Sequence; D003460:Crystallization; D018360:Crystallography, X-Ray; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000201:enzymology*; D006860:Hydrogen Bonding; D008956:Models, Chemical; D008958:Models, Molecular; D008969:Molecular Sequence Data; D019158:N-Acetylneuraminic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D007652:Oxo-Acid-Lyases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000145:classification / Q000378:metabolism; D011487:Protein Conformation; D016415:Sequence Alignment; D055672:Static Electricity; D013329:Structure-Activity Relationship; D013402:Sugar Alcohols / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014443:Tyrosine / Q000378:metabolism
D004791:Enzyme Inhibitors; D013402:Sugar Alcohols; C036137:2-deoxy-2,3-dehydro-N-acetylneuraminic acid; D014443:Tyrosine; D007652:Oxo-Acid-Lyases; C018728:N-acetylneuraminate lyase; D019158:N-Acetylneuraminic Acid